This refresh
Data-driven refresh September 23, 2026. The Top Picks are the Bull Rankings quality-growth screen — strong, growing businesses with durable returns at a fair price (PEG / EV-EBIT vs sector, ROIC, free cash flow). Scanned every US-listed common stock on NYSE, NASDAQ, NYSE American, and NYSE Arca (5,240 tickers); 1,696 scored on the quality-growth model (financials route to a separate card). Fundamentals from Yahoo Finance quoteSummary reconciled with as-reported SEC EDGAR filings; narrative authored by Groq (with Gemini and data-driven fallbacks).
Top 30 — quality compounders at a fair price
1. DLO — DLocal Limited · score 90.1
Software - Infrastructure · price $14.06 · 1Y $18.80 · 5Y $27.53 · 10Y $40.83
FCF $413m C · Rev +46.6% A · D/E 0.12 B+ · P/E 20.7x B+ · PEG 0.61 A-
Why now. Software - Infrastructure · market cap $4.2b. 15% off the 52-week high of $16.78. Revenue growing +47% — in hypergrowth territory. PEG 0.61 — paying under fair value for the growth rate. 10 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $18.80 (implying +32% upside).
Moat. Net margin 18% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 35% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Free cash flow runs well ahead of reported net income.
Risk. Software — competitive moat is durable until it isn't; watch net revenue retention, gross margin trends, and any new market entrant with a fundamentally lower price point.
Horizon. 1-3 yr $18.80 (analyst consensus (n=10)) — fundamentals + valuation re-rating. 5 yr $27.53 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $40.83 if current growth sustains into durable earnings power.
2. ADBE — Adobe Inc. · score 89.7
Software - Application · price $240.69 · 1Y $278.15 · 5Y $407.25 · 10Y $604.12
FCF $10.6b A- · Rev +12.0% B+ · D/E 0.57 C+ · P/E 13.4x A · PEG 0.60 A-
Why now. Adobe’s Digital Media subscription engine is the engine room of growth, delivering 12% revenue expansion and a rock‑solid 28% profit margin while generating $10.6B of free cash flow. Our model’s Quality pillar (92) reflects the extraordinary 61.9% ROE and the cheap PEG of 0.6, signaling a high‑quality, under‑priced growth story. The whole thesis hinges on the subscription moat continuing to compound earnings at double‑digit rates.
Moat. The Creative Cloud suite locks in photographers, video editors, designers and enterprises with multi‑year licenses, creating switching costs that preserve a >60% ROE driven by pricing power in the market‑leading digital‑media platform. Adobe’s integrated Digital Experience stack further deepens relationships with marketers and agencies, making it hard for rivals to replicate the end‑to‑end workflow.
Risk. A 1.42 beta and a debt‑to‑equity of 0.57 expose Adobe to market volatility and leverage risk, while the reverse‑DCF shows implied cash‑flow growth of –2% in year 1, well below the trailing 12% revenue growth, suggesting the market already prices in a slowdown. A breach of this low‑growth assumption would crush the valuation premise and trigger a sell‑off.
Horizon. 1-3 yr $278.15 (analyst consensus (n=33)) — fundamentals + valuation re-rating. 5 yr $407.25 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $604.12 if current growth sustains into durable earnings power.
3. NBIX — Neurocrine Biosciences, Inc. · score 88.9
Drug Manufacturers - Specialty & Generic · price $139.49 · 1Y $208.40 · 5Y $305.11 · 10Y $452.62
FCF $870m C+ · Rev +34.4% A · D/E 0.12 B+ · P/E 20.4x B+ · PEG 0.29 A
Why now. Drug Manufacturers - Specialty & Generic · market cap $14.5b. Down 24% from 52-week high of $186.12 — deep drawdown territory. Revenue growing +34% — in hypergrowth territory. PEG 0.29 — paying under fair value for the growth rate. 29 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $208.40 (implying +47% upside).
Moat. Net margin 21% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 19% is above 15% — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 123% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Horizon. 1-3 yr $208.40 (analyst consensus (n=29)) — fundamentals + valuation re-rating. 5 yr $305.11 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $452.62 if current growth sustains into durable earnings power.
4. HRMY — Harmony Biosciences Holdings, Inc. · score 88.3
Biotechnology · price $40.48 · 1Y $47.36 · 5Y $59.80 · 10Y $76.69
FCF $355m C · Rev +24.3% A- · D/E 0.16 B+ · P/E 13.1x A- · PEG 0.48 A
Why now. Biotechnology · market cap $2.4b. 7% off the 52-week high of $43.49. Revenue growing +24%, comfortably above the S&P median. PEG 0.48 — paying under fair value for the growth rate. 11 sell-side analysts publish a mean 1-yr target of $47.36 (implying +17% upside).
Moat. Net margin 19% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 18% is above 15% — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 196% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Horizon. 1-3 yr $47.36 (analyst consensus (n=11)) — multiple re-rating thesis requires a catalyst. 5 yr $59.80 at ~8% CAGR — dividend + buyback compounding. 10 yr $76.69 if the moat survives secular pressure.
5. PGY — Pagaya Technologies Ltd. · score 86.2
Software - Infrastructure · price $18.72 · 1Y $28.91 · 5Y $42.33 · 10Y $62.79
FCF $252m C · Rev +25.6% A- · D/E 1.34 C · P/E 13.3x A · PEG 0.04 A
Why now. The bull case hinges on Pagaya’s flagship Decline Monetization platform, which is unlocking hidden loan value and fueling a 25.6% YoY revenue surge. The business converts rejected applications into revenue streams, delivering $252 m of free‑cash‑flow and a cheap PE of 14.7x that the Bull Rankings model flags as a Value pillar score of 99 – the cheapest among peers. As long as the AI‑driven network keeps scaling, the compounding engine that drove this growth will persist, making the current price a deep‑value entry.
Moat. Pagaya’s moat lives in its AI‑powered Decline Monetization and Dual Look suite, which embed proprietary risk models into partner lenders’ workflows. Once a lender integrates the real‑time assessment engine, switching costs rise because the network learns lender‑specific credit patterns that are hard to replicate, preserving high ROE of 19.5% and pricing power in the U.S. fintech loan market.
Risk. The bear case centers on the stock’s extreme volatility (beta 5.37) and a capital structure that leans on debt (D/E 1.34), which could amplify downside if financing costs rise. Moreover, the Bull Rankings reverse‑DCF shows the market pricing a negative‑growth start (‑6% year 1) that is far below the actual 25.6% revenue growth, implying pessimism is already baked in; a slowdown or margin squeeze would trigger a sell‑off. Confirmation would be a breach of the 52‑week low at $10.40 or a widening of the debt ratio.
Horizon. 1-3 yr $28.91 (analyst consensus (n=11)) — fundamentals + valuation re-rating. 5 yr $42.33 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $62.79 if current growth sustains into durable earnings power.
6. NVDA — NVIDIA Corporation · score 86.1
Semiconductors · price $225.51 · 1Y $327.70 · 5Y $479.79 · 10Y $711.73
FCF $127.0b A · Rev +83.4% A · D/E 0.17 B+ · P/E 28.5x B · PEG 0.48 A
Why now. NVIDIA’s unrivaled position in data‑center AI infrastructure fuels an explosive 83.4% revenue growth and a massive $127.0 billion free‑cash‑flow run‑rate, while its 63.7% profit margin turns that growth into pure earnings. The Compute & Networking segment’s AI accelerators lock in recurring spend from hyperscale cloud providers, guaranteeing compounding top‑line expansion that will keep the business on a high‑growth trajectory. The thesis rests on the continued capture of AI‑driven data‑center spend.
Moat. NVIDIA’s moat lives in its AI‑accelerated GPU IP and the entrenched ecosystem of developers and cloud customers that cannot switch without massive redesign costs. The 84.2% ROE reflects pricing power derived from category leadership in data‑center GPUs, where each new architecture command premium pricing and drives sticky, high‑margin contracts. This combination of proprietary silicon, software stack, and switching barriers protects earnings for decades.
Risk. The stock trades at a lofty 28.9× forward P/E and a beta of 2.22, exposing investors to valuation compression if AI spend slows. Our reverse‑DCF shows the market assumes only a 48% FCF growth rate in year 1, well below the 83.4% revenue surge just delivered, indicating the price already embeds a slowdown narrative. A sustained dip in data‑center demand or a breakthrough competitor could trigger a sell‑off, confirming the bear case.
Horizon. 1-3 yr $327.70 (analyst consensus (n=59)) — fundamentals + valuation re-rating. 5 yr $479.79 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $711.73 if current growth sustains into durable earnings power.
7. GDDY — GoDaddy Inc. · score 85.7
Software - Infrastructure · price $96.38 · 1Y $105.19 · 5Y $154.01 · 10Y $228.46
FCF $1.7b C+ · Rev +7.4% B · D/E n/a · P/E 14.3x A- · PEG 0.57 A-
Why now. GoDaddy’s Applications & Commerce suite – especially the Websites + Marketing builder and Managed WordPress – is fueling a 7.4% revenue growth while the business churns out $1.7 B of free cash flow and delivers a solid 17.8% profit margin. Coupled with a cheap PEG of 0.57 and a P/E of 14.6, the Bull Rankings model awards a Quality‑growth score of 85.7, with Quality as its strongest pillar, underscoring the durability of cash generation. The thesis rests on the continued compounding of the web‑hosting and e‑commerce platform revenue stream, which the current fundamentals prove can sustain the upside to the analyst consensus target of $105.19.
Moat. The integrated A&C platform locks small‑business owners into a single ecosystem for site building, SEO tools, and e‑commerce, creating high switching costs and a sticky recurring‑revenue base. GoDaddy’s deep integration with the WordPress ecosystem and its proprietary design tools give it a cost‑advantaged, scalable distribution channel that rivals cannot replicate quickly.
Risk. The model’s softest pillar is Growth, and the reverse‑DCF shows the market pricing in a -15% FCF contraction in year 1, far below the trailing 7.4% revenue growth – a clear sign that investors are already pessimistic about near‑term momentum. If margin pressure or competitive pressure in the website‑builder space forces revenue growth to stall, the stock could fall back toward its 52‑week low of $71.59, confirming the bear case.
Horizon. 1-3 yr $105.19 (analyst consensus (n=16)) — fundamentals + valuation re-rating. 5 yr $154.01 at ~9% CAGR — compounding case rests on the competitive position widening. 10 yr $228.46 if current growth sustains into durable earnings power.
8. INTU — Intuit Inc. · score 85.6
Software - Application · price $286.80 · 1Y $405.60 · 5Y $593.84 · 10Y $880.92
FCF $8.7b B+ · Rev +13.9% B+ · D/E 0.44 B · P/E 17.4x A- · PEG 0.97 B+
Why now. Our model’s strongest pillar—Growth—shows Intuit’s QuickBooks and Mailchimp platforms compounding revenue at 13.9% YoY, underpinned by a 21.3% profit margin and a robust $8.7B free‑cash‑flow. This operating engine, combined with a low PEG of 0.97, fuels a clear path to out‑performance, and the whole thesis rests on sustaining that high‑margin, recurring‑revenue engine.
Moat. Intuit’s moat lives in the sticky QuickBooks ecosystem: small‑ and mid‑market businesses rely on integrated accounting, payroll, payments and financing, creating high switching costs and pricing power that drives a 24% ROE. The Mailchimp add‑on deepens customer lock‑in by bundling marketing automation with core financial tools, a combination rivals can’t replicate quickly.
Risk. The bear case centers on the reverse‑DCF implied growth of –9% in year 1, well below the trailing 13.9% revenue expansion, signaling that the market already prices in a slowdown; if revenue growth stalls further, the current P/E of 17.8 could look stretched and the stock could retreat toward the low end of the analyst range at $290. A confirmed deceleration would validate the pessimistic growth assumption and break the bull thesis.
Horizon. 1-3 yr $405.60 (analyst consensus (n=31)) — fundamentals + valuation re-rating. 5 yr $593.84 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $880.92 if current growth sustains into durable earnings power.
9. APP — AppLovin Corporation · score 84.1
Advertising Agencies · price $315.25 · 1Y $498.37 · 5Y $729.66 · 10Y $1,082
FCF $4.5b B · Rev +60.6% A · D/E 1.11 C+ · P/E 24.2x C+ · PEG 0.72 A-
Why now. The bull case hinges on AppLovin’s AI‑driven MAX in‑app bidding platform, which is fueling explosive top‑line expansion. Revenue is soaring +60.6% YoY while the business converts that into a stellar 64.6% profit margin and generates $4.5 B of free cash flow, giving the company a powerful engine for compounding. As long as MAX continues to lock developers into its real‑time auction, that growth runway stays intact – the thesis rests on sustaining this high‑velocity revenue compounding.
Moat. AppLovin’s moat lives in the lock‑in of developers to its MAX and Adjust suites: publishers hand over inventory to a real‑time competitive auction that maximizes yield, while advertisers rely on Adjust’s measurement backbone. Switching costs are high because developers must rebuild bidding and analytics stacks, and the AI‑optimization layer is hard to replicate quickly, preserving pricing power and cash conversion.
Risk. The bear case centers on the stock’s lofty valuation and volatility. A P/E of 24.2 is premium for an advertising agency, and a beta of 2.49 signals sharp price swings; any slowdown in the 60.6% revenue surge or a dip in the 64.6% margin would crush expectations. Moreover, debt‑to‑equity at 1.11 adds leverage risk if ad spend contracts, and a breach of the implied 30% free‑cash‑flow growth assumption would trigger a sell‑off.
Horizon. 1-3 yr $498.37 (analyst consensus (n=31)) — fundamentals + valuation re-rating. 5 yr $729.66 at ~18% CAGR — compounding case rests on the competitive position widening. 10 yr $1,082 if current growth sustains into durable earnings power.
10. CARG — CarGurus, Inc. · score 84.1
Internet Content & Information · price $30.57 · 1Y $42.00 · 5Y $61.49 · 10Y $91.22
FCF $315m C · Rev +13.9% B+ · D/E 0.70 B · P/E 15.8x B+ · PEG 0.71 A-
Why now. CarGurus’ Digital Deal platform is turning its massive dealer subscription base into a high‑margin, cash‑generating engine, fueling a 13.9% trailing‑year revenue growth while preserving an 18.2% profit margin and an eye‑popping 66.6% ROE. Those fundamentals sit under the Bull Rankings model’s strongest pillar – Quality (86) – confirming the business can reinvest profit into growth without diluting earnings. The thesis rests on the compounding power of Digital Deal and dealer subscriptions continuing to outpace the modest –7% year‑1 FCF growth implied by today’s price.
Moat. The platform’s dealer‑subscription network creates a two‑sided moat: dealers pay recurring fees for access to CarGurus’ high‑intent shopper audience, while shoppers rely on the site’s pricing algorithm and inventory depth, making switching costly. This lock‑in fuels the 66.6% ROE, reflecting pricing power that stems from CarGurus’ category leadership in online automotive matchmaking.
Risk. The Bull Rankings model flags a softest pillar – Value (81) – indicating the stock already trades on the cheap side of sector peers, yet the reverse‑DCF shows the market assumes a -7% FCF growth rate in year 1, well below the 13.9% revenue growth actually delivered. A slowdown in Digital Deal adoption or a rise in debt‑to‑equity above the current 0.7 could push the implied growth even lower, confirming the bear case if cash‑flow momentum stalls.
Horizon. 1-3 yr $42.00 (analyst consensus (n=12)) — fundamentals + valuation re-rating. 5 yr $61.49 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $91.22 if current growth sustains into durable earnings power.
11. DOCS — Doximity, Inc. · score 83.8
Health Information Services · price $26.57 · 1Y $29.94 · 5Y $43.84 · 10Y $65.04
FCF $306m C · Rev +11.2% B · D/E 0.01 A- · P/E 32.0x C+ · PEG 0.59 A-
Why now. DOCS’s moat lies in its AI‑driven Ask assistant and the Doximity newsfeed that lock U.S. physicians onto a single, data‑rich platform, fueling a virtuous loop of engagement and ad spend. The business is delivering 11.2% revenue growth YoY, a robust 25.5% profit margin, and $306 m of free cash flow while trading at a PEG of 0.59, all underpinned by our Bull Rankings model quality‑growth score of 83.8 (Quality 88, strongest pillar). The thesis rests on the platform’s ability to keep compounding this high‑margin cash generation as more clinicians adopt AI‑enhanced workflows.
Moat. The Ask AI assistant embeds directly into clinicians’ electronic health record workflows, creating a high switching cost for physicians who rely on its HIPAA‑compliant evidence retrieval. Coupled with a 18.2% ROE, this reflects pricing power from being the de‑facto professional network for U.S. doctors, a position competitors can’t replicate quickly without comparable data breadth and trust.
Risk. The stock’s valuation is stretched at a forward P/E of 31.6, well above the sector’s average, and the Bull Rankings model flags the softest pillar—Value—at 79, indicating the price already assumes optimism. A slowdown in revenue growth below the current 11.2% or a margin dip would validate the bear case, and a breach of the 52‑week low ($17.15) would trigger a sell‑off.
Horizon. 1-3 yr $29.94 (analyst consensus (n=18)) — fundamentals + valuation re-rating. 5 yr $43.84 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $65.04 if current growth sustains into durable earnings power.
12. EXLS — ExlService Holdings, Inc. · score 83.2
Information Technology Services · price $34.83 · 1Y $44.63 · 5Y $65.34 · 10Y $96.92
FCF $297m C · Rev +13.4% B+ · D/E 0.57 C+ · P/E 22.0x B+ · PEG 0.92 B+
Why now. The bull case hinges on EXLS’s dominant AI‑driven analytics platform for insurance and healthcare clients, which is fueling a 13.4% revenue growth while delivering a 32.3% ROE—a clear sign of pricing power in high‑margin contracts. Our Bull Rankings model awards a Quality‑Growth score of 83.2, with Growth as the strongest pillar, underscoring the durability of this compounding engine. Coupled with a $297 m free‑cash‑flow stream and a model‑signaled buy‑back program, the thesis rests on the business’s ability to keep compounding earnings at a rate that outpaces the modest 4% DCF growth baked into today’s price.
Moat. EXLS’s moat lives in its deep integration of AI analytics into claims management, underwriting support, and policy servicing for large insurers—processes that are costly to replace and create high switching costs. The 32.3% ROE reflects pricing power derived from being the preferred analytics partner across the Insurance and Healthcare segments, a position competitors can’t quickly replicate without comparable data assets and domain expertise.
Risk. The bear case focuses on the valuation stretch: a trailing P/E of 22.2 is elevated for a mid‑cap IT services name, and the Bull Rankings model’s Value pillar (77) signals the market already prices in slower growth than the 13.4% revenue expansion just delivered. If revenue growth decelerates toward the 4% DCF assumption, the stock could slump toward its 52‑week low of $24.85. A breach of the 4% growth floor would confirm the downside.
Horizon. 1-3 yr $44.63 (analyst consensus (n=8)) — fundamentals + valuation re-rating. 5 yr $65.34 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $96.92 if current growth sustains into durable earnings power.
13. LRN — Stride, Inc. · score 82.3
Education & Training Services · price $78.53 · 1Y $90.49 · 5Y $132.49 · 10Y $196.54
FCF $433m C · Rev +4.7% C+ · D/E 0.33 A- · P/E 11.1x A · PEG 0.43 A
Why now. The bull case hinges on Stride’s dominant online curriculum platform for software engineering and healthcare education, which is fueling a 13.4% profit margin and a solid 20.7% ROE. The business is trading at a P/E of 11 and a PEG of 0.43, reflecting the Bull Rankings model’s strongest pillar—Value—at 97, meaning the stock is among the cheapest in its sector. Coupled with a free‑cash‑flow generation of $433 m, the company can sustain buybacks while the education‑tech market continues to expand, making the current price a launchpad for upside.
Moat. Stride’s moat stems from its integrated end‑to‑end platform that bundles single sign‑on, learning management, student information, and analytics for state‑customized curricula, creating high switching costs for school districts and corporate training programs. The 20.7% ROE is driven by pricing power in this niche, as customers pay a premium for a turnkey solution that no pure‑play LMS can replicate quickly.
Risk. The bear case focuses on the softest pillar—Growth—scoring 67, signaling that revenue expansion is modest at only 4.7% YoY and the reverse DCF assumes a negative -12% FCF growth in year 1, which could turn into margin compression if the education budget cycle tightens. A breach of the 52‑week low around $60.61 would confirm that growth is stalling and the valuation premium is unjustified.
Horizon. 1-3 yr $90.49 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $132.49 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $196.54 if current growth sustains into durable earnings power.
14. CPAY — Corpay, Inc. · score 82.1
Software - Infrastructure · price $395.16 · 1Y $461.00 · 5Y $674.95 · 10Y $1,001
FCF $1.6b C+ · Rev +20.4% A- · D/E 2.75 D · P/E 24.1x B+ · PEG 0.76 A-
Why now. The bull case hinges on Corpay’s dominant corporate‑payments platform, especially its AP modernization and virtual‑card suite, which fuels a 20.4% revenue growth and a 22.7% profit margin. The business converts that top‑line surge into a 32.2% ROE, underscoring pricing power in a market where spend‑management solutions are becoming mission‑critical. As long as enterprises keep shifting expense processing to Corpay’s integrated suite, the compounding growth engine remains intact – the thesis rests on that relentless corporate‑spend adoption.
Moat. Corpay’s moat lives in its end‑to‑end corporate‑payments stack – from cross‑border payments to virtual cards and AP modernization – which locks in large enterprises that face high switching costs once their expense workflows are digitized. The 32.2% ROE reflects pricing leverage derived from being a category leader in spend‑management, a position competitors can’t replicate quickly without massive integration investments.
Risk. The bear case points to the valuation gap: the reverse‑DCF assumes only ~3% FCF growth, far below the trailing 20.4% revenue growth, implying the market is already pricing in a sharp slowdown. Coupled with a lofty PE of 24.1 and a debt‑to‑equity of 2.75, any earnings miss or margin compression would validate the pessimistic growth assumptions and trigger a sell‑off. A sustained dip in corporate spend or a successful challenger in the AP‑modernization space would confirm the risk.
Horizon. 1-3 yr $461.00 (analyst consensus (n=15)) — fundamentals + valuation re-rating. 5 yr $674.95 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $1,001 if current growth sustains into durable earnings power.
15. KTB — Kontoor Brands, Inc. · score 82.1
Apparel Manufacturing · price $65.69 · 1Y $97.50 · 5Y $142.75 · 10Y $211.76
FCF $422m C · Rev +34.3% A · D/E 2.06 C · P/E 13.3x A- · PEG 0.56 A-
Why now. Apparel Manufacturing · market cap $3.7b. Down 24% from 52-week high of $88.96 — deep drawdown territory. Revenue growing +34% — in hypergrowth territory. PEG 0.56 — paying under fair value for the growth rate. 10 sell-side analysts rate this a Buy with a mean 1-yr target of $97.50 (implying +44% upside).
Moat. ROE 43% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 158% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. D/E 2.06 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer.
Horizon. 1-3 yr $97.50 (analyst consensus (n=10)) — fundamentals + valuation re-rating. 5 yr $142.75 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $211.76 if current growth sustains into durable earnings power.
16. EPAM — EPAM Systems, Inc. · score 81.4
Information Technology Services · price $110.06 · 1Y $122.82 · 5Y $179.83 · 10Y $266.76
FCF $483m C · Rev +10.8% B · D/E 0.04 A- · P/E 14.9x A- · PEG 0.60 A-
Why now. EPAM’s digital platform engineering franchise is exploding, driven by its cloud‑enabled migration services that lock in multi‑year contracts with Fortune‑500 enterprises. The business is delivering 10.8% revenue growth YoY, a solid PE of 15.2 that sits well below the sector average, and a free‑cash‑flow generation of $483 m on a $5.8 b market cap – all of which underpin our Bull Rankings model Quality‑Growth score of 81.4. The strongest pillar, Value (89), tells us the stock is cheap relative to peers, and the compounding power of its platform services makes the thesis hinge on continued double‑digit growth.
Moat. EPAM’s moat lives in its end‑to‑end engineering platform that spans requirements analysis, cloud roadmap creation, AI‑enabled analytics, and smart automation. Large enterprises face high switching costs because migrating core applications across these integrated services requires deep technical knowledge and extensive re‑certification, a barrier that competitors can’t replicate quickly. This lock‑in fuels the company’s 11.4% ROE, reflecting pricing power from its category leadership in digital transformation.
Risk. The bear case centers on the implied reverse‑DCF growth of only 4% in year 1, fading to low single‑digit rates by year 10 – a trajectory that trails the actual 10.8% revenue growth and signals the market is already pricing in slower expansion. Coupled with a beta of 1.38 and a modest debt‑to‑equity of 0.04, any slowdown in cloud‑spending or a shift to lower‑margin consulting could compress the 7.2% profit margin and push the PE higher, confirming the downside.
Horizon. 1-3 yr $122.82 (analyst consensus (n=17)) — fundamentals + valuation re-rating. 5 yr $179.83 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $266.76 if current growth sustains into durable earnings power.
17. DECK — Deckers Outdoor Corporation · score 81.3
Footwear & Accessories · price $78.59 · 1Y $120.41 · 5Y $176.29 · 10Y $261.52
FCF $1.1b C+ · Rev +7.9% B · D/E 0.21 A- · P/E 11.2x A- · PEG 0.98 B+
Why now. The Bull Rankings model gives Deckers a Quality‑growth score of 81.3 anchored by a stellar Quality pillar of 96, and that reflects the company’s ability to monetize its premium UGG and high‑performance HOKA brands. With 7.9% revenue growth YoY, an 18.4% profit margin and a ROE of 44.1%, the business is compounding earnings faster than most peers, and the market’s 52‑week low of $77.37 shows ample upside to the analyst consensus target of $120.41. The thesis rests on continued demand for UGG’s lifestyle footwear and HOKA’s performance shoes, which together drive the sustainable earnings compounding.
Moat. Deckers’ moat comes from category leadership in premium casual and performance footwear: UGG dominates the high‑margin luxury‑lifestyle segment, while HOKA leads the fast‑growing performance‑running niche. This dual‑brand dominance fuels pricing power that translates into a ROE of 44.1%, a level only achievable when customers are willing to pay a premium that competitors can’t quickly match due to entrenched design patents and deep retail relationships.
Risk. The reverse‑DCF shows the market pricing in a negative -4% free‑cash‑flow growth in year 1, well below the trailing revenue growth of 7.9%, implying investors are already pessimistic about near‑term momentum. A slowdown in HOKA’s performance‑shoe demand or a shift in consumer taste away from UGG could compress the 18.4% profit margin and trigger a sell‑off, especially with a beta of 1.15 amplifying market volatility. A sustained miss on the implied growth trajectory would confirm the bear case.
Horizon. 1-3 yr $120.41 (analyst consensus (n=22)) — fundamentals + valuation re-rating. 5 yr $176.29 at ~18% CAGR — compounding case rests on the competitive position widening. 10 yr $261.52 if current growth sustains into durable earnings power.
18. TTD — The Trade Desk, Inc. · score 81.2
Advertising Agencies · price $12.68 · 1Y $13.60 · 5Y $19.91 · 10Y $29.54
FCF $863m C+ · Rev +11.6% B · D/E 0.17 A- · P/E 15.1x B+ · PEG 1.00 B+
Why now. The Trade Desk’s moat in programmatic CTV and video inventory fuels a 13.6% profit margin and a robust $863 m free‑cash‑flow generation, while revenue still climbs 11.6% YoY. Our Bull Rankings model awards an 81.2/100 quality‑growth score, with Quality as the strongest pillar, underscoring the durability of its technology platform and agency relationships. The price already embeds a pessimistic reverse‑DCF outlook—‑14% growth in year 1 versus the 11.6% revenue growth delivered—so any lift in actual growth will unleash upside. The thesis rests on continued CTV adoption that keeps the margin and cash flow expanding.
Moat. TTD’s platform locks agencies and advertisers into a data‑rich, cross‑device buying ecosystem that spans TV, streaming, mobile and DOOH, creating high switching costs and a network effect that rivals can’t replicate quickly. Its 15.8% ROE reflects pricing power derived from being the de‑facto infrastructure for premium video inventory, allowing it to capture outsized returns on capital.
Risk. The stock trades at a modest 15.7× P/E, but the reverse‑DCF shows the market assumes a near‑term revenue slowdown to ‑14% growth, signaling that investors fear a deceleration in CTV spend or a shift to rival platforms. A sustained dip in ad spend or a loss of agency spend could push revenue growth below the current 11.6% pace, confirming the bear case. The key signal would be a quarter where revenue growth falls under 5% and margin compresses.
Horizon. 1-3 yr $13.60 (analyst consensus (n=30)) — fundamentals + valuation re-rating. 5 yr $19.91 at ~9% CAGR — compounding case rests on the competitive position widening. 10 yr $29.54 if current growth sustains into durable earnings power.
19. RMD — ResMed Inc. · score 79.7
Medical Instruments & Supplies · price $222.30 · 1Y $247.56 · 5Y $362.46 · 10Y $537.68
FCF $1.6b C+ · Rev +9.9% B · D/E 0.13 B+ · P/E 21.3x B+ · PEG 1.30 B
Why now. The bull case hinges on ResMed’s dominant AirView cloud platform that locks sleep clinics, hospitals and home‑care providers into a data‑rich ecosystem, driving recurring revenue from its Sleep and Breathing Health segment. The business is underpinned by a 26.9% profit margin, a 23.1% ROE and 9.9% revenue growth YoY, all while trading at a modest PE of 21.3x versus peers. With our model’s Quality pillar at 90 (the strongest) and a Value score of 69 indicating the stock is on the cheap side of its sector, the thesis rests on the durable cash‑flow engine and the upside baked into the 1‑yr consensus target.
Moat. ResMed’s moat stems from the AirView platform and its suite of cloud‑connected devices—ApneaLink Air, NightOwl and EasyCare Tx—that embed proprietary algorithms and patient data into a single, non‑transferable workflow for clinicians. This creates high switching costs for sleep‑lab operators and leverages the company’s 23.1% ROE, which reflects pricing power derived from category leadership in digital sleep‑apnea diagnostics.
Risk. The bear case focuses on the elevated valuation: a PE of 21.3x is high for a market‑cap of $32.0 B and leaves little margin for error if revenue growth decelerates from the current 9.9% pace. A modest debt‑to‑equity of 0.13 offers little cushion if competitive pressure forces margin compression, and a beta of 0.77 means the stock won’t rally sharply on broader market rallies. A sustained slowdown below the reverse‑DCF implied 5% free‑cash‑flow growth would trigger a price correction toward the lower end of the analyst range.
Horizon. 1-3 yr $247.56 (analyst consensus (n=16)) — fundamentals + valuation re-rating. 5 yr $362.46 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $537.68 if current growth sustains into durable earnings power.
20. BSX — Boston Scientific Corporation · score 79.3
Medical Devices · price $44.62 · 1Y $61.07 · 5Y $89.41 · 10Y $132.64
FCF $3.6b B · Rev +13.5% B+ · D/E 0.50 B · P/E 18.1x A- · PEG 0.61 A-
Why now. The Bull Rankings model gives BSX a 79.3 quality‑growth score, with Growth as its strongest pillar, because the MedSurg and Cardiovascular segments are expanding at a 13.5% revenue‑growth rate while delivering a solid 17.5% profit margin. Free cash flow of $3.6 B and a low debt‑to‑equity of 0.5 let management keep buying back shares, reinforcing the upside. The reverse‑DCF shows the market assumes a near‑term FCF decline (‑2% year 1) that is well below the actual growth rate, meaning the current price already embeds a discount to the business’s real momentum – the thesis rests on that hidden upside.
Moat. BSX’s moat lives in its single‑use endoscopic devices and cardiovascular platforms, which hospitals adopt for procedural safety and regulatory compliance, creating high switching costs. The company’s patented delivery systems and integrated scope ecosystems lock in large health‑system customers, while the modest 0.5 debt‑to‑equity ratio gives it financial flexibility to out‑spend rivals on R&D and buybacks.
Risk. The bear case hinges on the market’s expectation that growth will taper, as the reverse‑DCF already assumes a sub‑growth FCF trajectory and analysts price the stock at a 52‑week high of $105.65, leaving limited upside. If revenue growth falls below the current 13.5% pace and margins compress, the 18.1× P/E will look stretched and the buyback engine could sputter. A sustained slowdown would validate the implied negative‑growth assumption and crush the upside.
Horizon. 1-3 yr $61.07 (analyst consensus (n=29)) — fundamentals + valuation re-rating. 5 yr $89.41 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $132.64 if current growth sustains into durable earnings power.
21. YUMC — Yum China Holdings, Inc. · score 78.7
Restaurants · price $40.85 · 1Y $61.91 · 5Y $90.65 · 10Y $134.47
FCF $940m C+ · Rev +8.8% B · D/E 0.38 A- · P/E 15.0x B+ · PEG 0.93 B+
Why now. Yum China’s KFC franchise is cementing its dominance in China’s fast‑food delivery boom, driving a 8.8% revenue growth while generating $940 m of free cash flow and delivering an 18.2% ROE. Our Bull Rankings model awards a 78.7 quality‑growth score, with Quality as the strongest pillar, underscoring the business’s cash‑rich, high‑return profile. The thesis rests on the compounding power of KFC’s delivery‑centric expansion, which should keep the growth engine humming beyond the modest 3% DCF assumption baked into today’s price.
Moat. Yum China’s moat lives in its massive, franchised KFC and Pizza Hut footprint across China, paired with an integrated online delivery platform that locks in repeat traffic and gives the company pricing leverage—evidenced by an 18.2% ROE that outpaces peers. The sheer scale of its restaurant network and proprietary delivery logistics create switching costs that competitors can’t quickly replicate.
Risk. The Bull Rankings model’s reverse‑DCF implies only a 3% FCF growth trajectory, well below the 8.8% revenue growth the company just delivered, suggesting the market is already pricing in a slowdown; a failure to sustain current growth would push the stock toward its 52‑week low of $40.15. Additionally, the current P/E of 15.2, while modest, leaves little room for error if margins compress, and a breach of the 52‑week high $58.39 would confirm bearish pressure.
Horizon. 1-3 yr $61.91 (analyst consensus (n=20)) — fundamentals + valuation re-rating. 5 yr $90.65 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $134.47 if current growth sustains into durable earnings power.
22. DXCM — DexCom, Inc. · score 78.6
Medical Devices · price $87.73 · 1Y $94.48 · 5Y $138.33 · 10Y $205.20
FCF $1.4b C+ · Rev +15.5% B+ · D/E 0.53 B · P/E 34.7x C+ · PEG 1.37 B
Why now. DexCom’s market‑leading G7 CGM platform is set to dominate the expanding continuous glucose monitoring market, driven by 15.5% revenue growth, a robust 20.1% profit margin and an elite 38.1% ROE. Our Bull Rankings model rates the stock at a 78.6 quality‑growth score, with Quality as the strongest pillar, underscoring the durable competitive edge of its integrated CGM ecosystem. The thesis hinges on the G7’s continued adoption across endocrinologists and diabetes centers, compounding earnings at a rate that outpaces peers.
Moat. DexCom’s moat stems from its end‑to‑end CGM solution—G7, G7 15‑Day, Dexcom ONE+, and the Share platform—locked into physician‑prescribed care pathways, creating high switching costs for patients and clinicians. The 38.1% ROE reflects pricing power derived from category leadership and the ability to command premium pricing for its FDA‑cleared, data‑rich devices, a barrier hard for new entrants to replicate quickly.
Risk. The biggest headwind is the elevated valuation: a forward P/E of 35.4 implies the market is pricing in growth well above the trailing 15.5% revenue pace, and any slowdown would pressure the stock. A beta of 1.42 adds volatility, while a debt‑to‑equity of 0.53 leaves limited cushion if capital‑intensive R&D overruns occur. A miss on the next earnings beat would trigger a sell‑off, confirming the bear case.
Horizon. 1-3 yr $94.48 (analyst consensus (n=25)) — fundamentals + valuation re-rating. 5 yr $138.33 at ~9% CAGR — compounding case rests on the competitive position widening. 10 yr $205.20 if current growth sustains into durable earnings power.
23. MELI — MercadoLibre, Inc. · score 78.3
Internet Retail · price $1799.24 · 1Y $2,265 · 5Y $3,316 · 10Y $4,919
FCF $12.4b A- · Rev +46.0% A · D/E 1.69 C+ · P/E 48.8x D · PEG 1.00 B+
Why now. The bull case hinges on Mercado Pago’s expanding financial services moat, which is fueling a staggering 46% YoY revenue surge while the platform generates $12.4B of free cash flow and delivers a stellar 23.8% ROE. Our Bull Rankings model rates MELI at a 78.3 quality‑growth score, with Growth as the strongest pillar, underscoring the durability of this compounding engine. The thesis rests on the continued capture of e‑commerce and fintech spend in Brazil, Mexico, and Argentina, where network effects lock in users and lock‑in revenue growth.
Moat. MELI’s moat lives in the seamless integration of its Marketplace and Mercado Pago ecosystem, creating a two‑sided network that makes switching costly for both buyers and sellers. The high ROE stems from pricing power as the leading e‑commerce platform in its core Latin American markets, allowing it to monetize transaction fees and credit services at margins competitors can’t easily match.
Risk. The bear case points to the valuation premium: a trailing P/E of 48.8 and a reverse‑DCF that assumes year‑1 free‑cash‑flow growth of –8%, well below the recent 46% revenue expansion, implying the market has already baked in a sharp slowdown. A debt‑to‑equity of 1.69 and beta of 1.31 amplify downside if growth decelerates or margins compress. A sustained miss on the implied growth trajectory would trigger a re‑rating and invalidate the bull thesis.
Horizon. 1-3 yr $2,265 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $3,316 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $4,919 if current growth sustains into durable earnings power.
24. ACN — Accenture plc · score 77.9
Information Technology Services · price $183.52 · 1Y $191.61 · 5Y $280.54 · 10Y $416.16
FCF $12.6b A- · Rev +6.7% C+ · D/E 0.25 B · P/E 14.7x A- · PEG 1.35 B
Why now. Accenture’s unrivaled depth in cloud‑enabled digital transformation fuels a compounding engine anchored in its 6.7% revenue growth, robust 10.7% profit margin and a stellar ROE of 24.4%. Our Bull Rankings model rates the company a 77.9 quality‑growth score, with Quality as the strongest pillar, underscoring the durability of its high‑margin consulting and managed services franchise. The thesis rests on the continued rollout of its intelligent platform and AI‑driven automation services across Fortune‑500 clients, which should keep the growth momentum alive for years to come.
Moat. Accenture’s moat lives in its end‑to‑end delivery ecosystem – from strategy and consulting to systems integration, cloud, AI and managed services – that locks in multi‑year contracts with large enterprises and creates high switching costs. Its 24.4% ROE reflects pricing power derived from category leadership in digital transformation, a capability rivals cannot replicate quickly without comparable scale and talent depth.
Risk. The bear case centers on the price assuming a slower free‑cash‑flow growth trajectory (‑7% in year 1 fading to 3% by year 10) than the 6.7% revenue growth just delivered, signaling that investors are already pricing in a deceleration. A sustained slowdown in consulting spend or a sharp rise in the 1.09 beta‑adjusted cost of capital could push the PE of 14.7 higher, eroding the valuation cushion. A miss on the next earnings beat that widens the gap between actual and implied growth would confirm the downside.
Horizon. 1-3 yr $191.61 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $280.54 at ~9% CAGR — compounding case rests on the competitive position widening. 10 yr $416.16 if current growth sustains into durable earnings power.
25. VRT — Vertiv Holdings Co · score 77.5
Electrical Equipment & Parts · price $248.78 · 1Y $338.15 · 5Y $495.09 · 10Y $734.43
FCF $2.9b B · Rev +26.2% A- · D/E 0.70 B · P/E 55.8x D · PEG 0.85 B+
Why now. Vertiv’s dominance in critical data‑center power and thermal management fuels a compounding revenue engine – the business is growing 26.2% YoY while delivering a hefty 15.1% profit margin and a razor‑thin PE of 57.3 that still ranks on the cheap side of peers (Value pillar 60). Our Bull Rankings model scores Growth at 91, the strongest pillar, underscoring that the upside lives in the relentless demand for UPS, rack power distribution and liquid‑cooled cooling solutions across hyperscale and edge data centers. The thesis rests on this secular demand staying ahead of the 39% year‑1 FCF growth baked into today’s price.
Moat. Vertiv’s integrated modular solutions and lifecycle services lock in long‑term contracts with hyperscale operators, creating high switching costs and predictable recurring revenue. The 36.4% ROE reflects pricing power derived from being the go‑to supplier of single‑phase UPS and busbar systems in mission‑critical environments, a capability rivals can’t replicate quickly without massive capex and certification hurdles.
Risk. The stock trades at a lofty 57.3× PE despite a 26.2% revenue surge, meaning any slowdown in data‑center capex or a shift to cheaper commodity power solutions would crush valuation multiples. A beta of 2.08 amplifies market volatility, and the 0.7 debt‑to‑equity ratio leaves limited headroom if interest rates rise. A breach of the 39% implied FCF growth assumption would trigger a sharp re‑rating, confirming the bear case.
Horizon. 1-3 yr $338.15 (analyst consensus (n=26)) — fundamentals + valuation re-rating. 5 yr $495.09 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $734.43 if current growth sustains into durable earnings power.
26. ONON — On Holding AG · score 77.3
Footwear & Accessories · price $30.16 · 1Y $42.88 · 5Y $62.78 · 10Y $93.13
FCF $523m C+ · Rev +30.0% A · D/E 0.29 A- · P/E 21.1x C+ · PEG 0.45 A
Why now. ONON’s explosive 30% FY revenue growth is being driven by its performance‑running footwear line, which dominates the premium running segment across Europe and North America. Coupled with a healthy 6.8% profit margin and a market‑cap of $10.1 B, the stock is positioned to compound earnings as the brand expands its direct‑to‑consumer stores and e‑commerce reach. The thesis rests on the persistence of this high‑velocity growth in the premium running market.
Moat. The brand’s proprietary Cloud® cushioning technology locks in performance‑oriented runners who value the unique ride feel, creating a switching cost that rivals can’t replicate quickly. This product advantage fuels repeat purchases and allows ONON to command pricing power, underpinning its current 12.5% ROE despite a modest 0.29 debt‑to‑equity ratio.
Risk. A lofty PE of 21.1 and a beta of 2.08 signal that the stock is highly sensitive to market swings, and the Bull Rankings model flags “Diluting shareholders” as a cautionary signal. If revenue growth decelerates below the trailing 30% and the implied free‑cash‑flow growth of 24% in year 1 proves unsustainable, the valuation could collapse, confirming the bear case.
Horizon. 1-3 yr $42.88 (analyst consensus (n=30)) — fundamentals + valuation re-rating. 5 yr $62.78 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $93.13 if current growth sustains into durable earnings power.
27. WMG — Warner Music Group Corp. · score 77.3
Entertainment · price $27.16 · 1Y $37.75 · 5Y $55.27 · 10Y $81.99
FCF $836m C+ · Rev +12.9% B+ · D/E 4.53 D · P/E 21.7x B · PEG 0.50 A
Why now. The single most compelling driver is Warner Music’s ever‑expanding catalog monetization across Recorded Music and Publishing, which is already delivering 12.9% revenue growth and $836 m of free cash flow. Coupled with an industry‑leading ROE of 78.7% and a sub‑1.0 PEG of 0.49, the business compounds earnings at a rate that mirrors its cash‑flow growth, making the current price a launchpad for sustained upside.
Moat. Warner’s moat rests on its two‑million‑song composition library and the exclusive rights to monetize that IP through licensing, streaming, and sync deals—assets that cannot be replicated quickly. This deep catalog fuels pricing power, evident in the 78.7% ROE, and locks in long‑term revenue streams from record labels, advertisers, and media producers.
Risk. The biggest headwind is the balance sheet: a debt‑to‑equity of 4.53 combined with a beta of 1.3 means any market pull‑back or rising rates could pressure cash flow and force dividend cuts, eroding the upside. A breach of the dividend‑raising signal would confirm the bear case.
Horizon. 1-3 yr $37.75 (analyst consensus (n=16)) — fundamentals + valuation re-rating. 5 yr $55.27 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $81.99 if current growth sustains into durable earnings power.
28. CI — The Cigna Group · score 77.1
Healthcare Plans · price $268.27 · 1Y $339.36 · 5Y $496.86 · 10Y $737.05
FCF $9.1b B+ · Rev +11.3% B · D/E 0.74 C+ · P/E 11.1x A · PEG 0.75 A-
Why now. The bull case hinges on Evernorth’s pharmacy‑benefit‑management franchise, which is expanding faster than the broader health‑plan market. Revenue is climbing +11.3% YoY while free cash flow sits at a robust $9.1 B, and the stock trades at a modest PE of 11.1x—all underscored by the Bull Rankings model’s strongest pillar, Value, which rates the stock at 89/100, signaling deep cheapness. The thesis rests on the ability of Evernorth to keep compounding this double‑digit top‑line growth into higher cash yields.
Moat. Evernorth’s integrated pharmacy‑benefit services lock employers and insurers into a high‑touch network of formulary design, utilization review, and specialty drug distribution, creating switching costs that competitors can’t quickly replicate. The 16.8% ROE reflects pricing power derived from this whole‑person health platform, turning the cost advantage into sustainable earnings.
Risk. The bear case points to the thin 2.3% profit margin and a reverse‑DCF that assumes year‑1 free‑cash‑flow growth of –12%, well below the 11.3% revenue growth just delivered—implying the market is already pricing in a slowdown. If margins compress further or the pharmacy business faces pricing pressure, the stock could retreat toward its 52‑week low of $239.51. A breach of that low would confirm the downside risk.
Horizon. 1-3 yr $339.36 (analyst consensus (n=25)) — fundamentals + valuation re-rating. 5 yr $496.86 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $737.05 if current growth sustains into durable earnings power.
29. NFLX — Netflix, Inc. · score 76.7
Entertainment · price $71.36 · 1Y $92.93 · 5Y $136.05 · 10Y $201.83
FCF $11.2b A- · Rev +16.0% B+ · D/E 0.55 B+ · P/E 22.4x B · PEG 1.25 B
Why now. Netflix’s global streaming platform is locked into a relentless subscriber expansion, driven by its ever‑growing library of TV series, documentaries, feature films and games. The business is delivering 16% revenue growth YoY, 28.2% profit margin and an eye‑popping 45.3% ROE, all while the Bull Rankings model flags a Quality‑growth score of 76.7 anchored by a top‑tier Quality pillar. The thesis rests on the ability to compound this high‑margin growth through deeper international penetration and premium‑tier pricing, keeping cash conversion robust.
Moat. The moat lives in Netflix’s unmatched content ecosystem and data‑driven personalization that lock in binge‑watching habits across devices, creating a high switching cost for members. Its 45.3% ROE stems from pricing power earned as the category leader in streaming, allowing it to reinvest free cash flow of $11.2 B into original productions that competitors can’t replicate quickly.
Risk. The bear case centers on the market pricing in aggressive growth: the reverse‑DCF implies a 29% FCF growth rate in year 1, far above the 16% trailing revenue growth, meaning any slowdown would crush valuation. Coupled with a high beta of 1.53 and a forward P/E of 22.7, a modest miss on subscriber growth or margin compression would trigger a sharp correction. Confirmation would be a quarterly earnings miss that pushes the 52‑week low toward $65.08.
Horizon. 1-3 yr $92.93 (analyst consensus (n=45)) — fundamentals + valuation re-rating. 5 yr $136.05 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $201.83 if current growth sustains into durable earnings power.
30. VEEV — Veeva Systems Inc. · score 76.7
Health Information Services · price $270.75 · 1Y $297.30 · 5Y $435.27 · 10Y $645.70
FCF $1.7b C+ · Rev +16.5% B+ · D/E 0.02 A- · P/E 44.3x C · PEG 1.16 B+
Why now. The bull case hinges on Veeva’s dominant Veeva Vault CRM Suite, which locks pharmaceutical and biotech customers into a single, cloud‑native workflow for sales, medical content, and analytics. That stickiness fuels a revenue growth rate of 16.5% YoY while the business delivers a robust 29.3% profit margin and a free‑cash‑flow generation of $1.7 B, giving investors a high‑quality earnings engine. The thesis rests on the fact that the company can keep compounding this growth as life‑science firms double‑down on digital transformation.
Moat. Veeva’s moat is the integrated Commercial Cloud platform that combines CRM, PromoMats, Crossix and OpenData, creating a data‑rich ecosystem that is costly for customers to replace. The deep, industry‑specific data (OpenData) and analytics (Crossix) embed Veeva into drug‑launch cycles, while the 13.7% ROE reflects pricing power from being the de‑facto standard for life‑science cloud software.
Risk. The bear case centers on the lofty PE ratio of 42.8, which implies the market is already pricing in near‑term growth; any slowdown from the current 16.5% revenue growth would expose the valuation to a sharp correction. A modest rise in debt (though currently low at a 0.02 debt‑to‑equity) or a market‑wide shift to lower‑cost SaaS alternatives could compress margins, and a breach of the 52‑week low at $148.05 would signal the downside breakout.
Horizon. 1-3 yr $297.30 (analyst consensus (n=27)) — fundamentals + valuation re-rating. 5 yr $435.27 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $645.70 if current growth sustains into durable earnings power.
Methodology footnote
Every pick on this list comes out of the same quality-growth model — one 0–100 score blending quality, growth, and value — applied to every US-listed common stock with a market cap above $1B. Each pick's score breakdown is auditable from the home page — click the ticker on the rankings page to see exactly which grades produced the number. Not investment advice. See terms for full disclosures.